Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) shot up 1.6% during mid-day trading on Monday . The stock traded as high as $71.23 and last traded at $70.09. 8,219,791 shares were traded during trading, a decline of 29% from the average session volume of 11,580,188 shares. The stock had previously closed at $68.96.
Analyst Ratings Changes
Several research firms have issued reports on TEM. Loop Capital cut their price target on shares of Tempus AI from $57.00 to $52.00 and set a "buy" rating for the company in a research report on Tuesday, January 14th. Guggenheim began coverage on shares of Tempus AI in a report on Monday, December 9th. They set a "buy" rating and a $74.00 target price for the company. Bank of America increased their target price on shares of Tempus AI from $52.00 to $54.00 and gave the stock a "neutral" rating in a report on Friday, December 13th. TD Cowen reiterated a "buy" rating and set a $74.00 target price (up from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Finally, Piper Sandler reiterated a "neutral" rating and set a $70.00 target price (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $58.55.
Read Our Latest Report on Tempus AI
Tempus AI Stock Up 6.8 %
The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The company's fifty day simple moving average is $46.60 and its 200 day simple moving average is $50.32.
Insiders Place Their Bets
In other Tempus AI news, major shareholder Bradley A. Keywell sold 265,000 shares of the firm's stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $35.10, for a total transaction of $9,301,500.00. Following the completion of the transaction, the insider now owns 15,218,365 shares of the company's stock, valued at approximately $534,164,611.50. This trade represents a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director David R. Epstein sold 620 shares of the firm's stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total transaction of $25,922.20. Following the transaction, the director now directly owns 27,894 shares of the company's stock, valued at $1,166,248.14. This represents a 2.17 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 2,401,779 shares of company stock worth $115,707,361 over the last three months.
Hedge Funds Weigh In On Tempus AI
A number of institutional investors and hedge funds have recently made changes to their positions in the business. First Horizon Advisors Inc. bought a new stake in shares of Tempus AI during the third quarter valued at approximately $30,000. Operose Advisors LLC bought a new stake in shares of Tempus AI during the fourth quarter valued at approximately $25,000. Farther Finance Advisors LLC bought a new stake in shares of Tempus AI during the fourth quarter valued at approximately $34,000. Prestige Wealth Management Group LLC increased its position in shares of Tempus AI by 910.4% during the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock valued at $36,000 after acquiring an additional 965 shares in the last quarter. Finally, NewEdge Advisors LLC bought a new stake in shares of Tempus AI during the fourth quarter valued at approximately $49,000. Institutional investors own 24.22% of the company's stock.
Tempus AI Company Profile
(
Get Free Report)
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Further Reading
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
